Last updated 1 month ago
Novo Nordisk, a Danish biopharmaceutical company, disclosed a data breach affecting clinical trial patients. The breach was publicly announced on June 14, 2026, via an incident notice. The exact number of records affected and the discovery date were not specified in the article.
The attack involved unauthorized access to systems containing clinical trial patient data. The initial access vector and exploitation technique were not detailed, but the breach targeted sensitive patient information. No specific threat actor or ransomware group was attributed, and no CVE references were provided.
The article did not mention any regulatory filings, litigation, ransom payment, or remediation milestones. Novo Nordisk advised affected clinical trial patients to remain vigilant against potential misuse of their data.
Unauthorized access to clinical trial patient data
Novo Nordisk's breach underscores the need for biopharma companies to implement robust access controls and monitoring for systems handling clinical trial data. The lack of disclosed attack details suggests that organizations in this sector should prioritize threat detection and response capabilities to quickly identify unauthorized access to sensitive patient information.
Sign in to join the discussion.
Company
Industry
Location
Disclosed
Records Affected
Attack Vector